Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of ... MarketWatch (press release) Results showed that the safety profile of NULOJIX through year 4 was consistent compared with results at year 3 with no new safety signals being identified, and that the renal function benefit versus cyclosporine was maintained through 4 years in ... |
